Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 3

1(14.3%)

N/A

1(14.3%)

Phase 2

1(14.3%)

7Total

Phase 1(4)

Phase 3(1)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06134401Not ApplicableNot Yet Recruiting

Nebulised Hypertonic Saline to Decrease Respiratory Exacerbations in Neuromuscular Disease or Neurodisability

Role: collaborator

NCT01955980Phase 1Completed

Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis

Role: lead

NCT01946711Phase 1Completed

Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi

Role: lead

NCT04176328Phase 1Completed

Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients

Role: collaborator

NCT01334892Phase 2Terminated

L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients

Role: lead

NCT01439958Phase 3Terminated

Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS)

Role: lead

NCT01953367Phase 1Completed

Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects

Role: lead

All 7 trials loaded